Cargando…
Perception to Hydroxyurea Therapy in Patients with Sickle Cell Disease: Report from 3 Centers
BACKGROUND: Hydroxyurea (HU) is an hemoglobin F inducing agent used in the treatment of sickle cell disease (SCD). AIM: The aim of this study is to determine the perception of HU by people living with SCD. MATERIALS AND METHODS: A pretested questionnaire was self-administered to known cases of SCD a...
Autores principales: | Korubo, Kaladada I., Onodingene, Nkemsinachi Maryanne, Okoye, Helen Chioma, Omunakwe, Hannah E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378460/ https://www.ncbi.nlm.nih.gov/pubmed/34213480 http://dx.doi.org/10.4103/aam.aam_36_20 |
Ejemplares similares
-
Bortezomib Prescription Pattern for the Treatment of Multiple Myeloma
by Hematologists in Nigeria
por: Korubo, Kaladada I., et al.
Publicado: (2017) -
Erratum: Perception to Hydroxyurea Therapy in Patients with Sickle Cell Disease: Report from 3 Centers
Publicado: (2021) -
Presenting features and treatment outcomes of chronic lymphocytic leukaemia in a resource poor Southern Nigeria
por: Madu, Anazoeze Jude, et al.
Publicado: (2019) -
Chronic Lymphocytic Leukemia: Prognostic Factors at Presentation in a Resource-Limited Center
por: Korubo, Kaladada Ibitrokoemi, et al.
Publicado: (2021) -
Effective control of sickle cell disease with hydroxyurea therapy
por: Singh, Harminder, et al.
Publicado: (2010)